Peptone valuation, funding and investors
Peptone works in small-molecule therapeutics design and development, based in Bellinzona, Switzerland. Founded in 2018, it has about 45 employees.
- Last round
- Series A · $40.0M · Jun 2022
- Valuation at last round
- $128M · implied
- Headcount
- 45 · flat
- Grade
- D
- Founded
- 2018
Peptone valuation today
VCMC values Peptone at $157M today, with a range of $12.9M to $378M and a grade of D. The valuation starts from its last funding round, a Series A round in Jun 2022.
Valuation by date (109 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2018 | $5.66M | $2.06M – $15.6M | $7.76M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $5.82M | $2.12M – $16.0M | $7.97M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $5.96M | $2.17M – $16.4M | $8.17M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $6.12M | $2.23M – $16.8M | $8.39M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $6.28M | $2.29M – $17.3M | $8.61M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $6.45M | $2.35M – $17.7M | $8.85M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $6.62M | $2.41M – $18.2M | $9.08M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $6.80M | $2.48M – $18.7M | $9.17M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $6.99M | $2.54M – $19.2M | $9.25M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $7.17M | $2.61M – $19.7M | $9.34M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $7.36M | $2.68M – $20.2M | $9.42M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $7.56M | $2.75M – $20.8M | $9.51M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $7.76M | $2.83M – $21.3M | $9.59M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $7.97M | $2.90M – $21.9M | $9.68M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $8.17M | $2.97M – $22.4M | $9.76M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $8.39M | $3.05M – $23.1M | $9.85M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $8.61M | $3.14M – $23.7M | $9.94M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $8.85M | $3.22M – $24.3M | $10.0M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $9.08M | $3.30M – $24.9M | $10.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $9.17M | $3.34M – $25.2M | $10.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $9.25M | $3.37M – $25.4M | $10.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $9.34M | $3.40M – $25.6M | $10.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $9.42M | $3.43M – $25.9M | $10.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $9.51M | $3.46M – $26.1M | $10.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $9.59M | $3.49M – $26.4M | $10.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $9.68M | $3.52M – $26.6M | $10.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $9.76M | $3.55M – $26.8M | $10.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $9.85M | $3.59M – $27.1M | $11.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $9.94M | $3.62M – $27.3M | $11.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $10.0M | $3.65M – $27.6M | $11.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $10.1M | $3.69M – $27.8M | $11.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $10.2M | $3.72M – $28.1M | $11.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $10.3M | $3.75M – $28.3M | $11.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $10.4M | $3.79M – $28.6M | $11.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $10.5M | $3.82M – $28.8M | $11.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $10.6M | $3.86M – $29.1M | $11.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2021 | $8.16M | $2.97M – $22.4M | $9.09M (+11%) | before first round | 3 | unknown | D | 0% |
| 9 Jan 2021 | $12.8M | $8.37M – $38.8M | $25.5M (+100%) | after a round | 3 | unknown | C | 0% |
| 1 Feb 2021 | $13.3M | $8.37M – $38.8M | $25.5M (+91%) | after a round | 3 | unknown | C | 0% |
| 1 Mar 2021 | $14.1M | $8.37M – $38.8M | $25.5M (+81%) | after a round | 3 | unknown | C | 0% |
| 1 Apr 2021 | $14.9M | $8.37M – $38.8M | $25.5M (+71%) | after a round | 3 | unknown | C | 0% |
| 1 May 2021 | $15.8M | $8.37M – $38.8M | $25.5M (+61%) | after a round | 3 | unknown | C | 0% |
| 1 Jun 2021 | $16.7M | $8.37M – $38.8M | $25.5M (+52%) | after a round | 3 | unknown | C | 0% |
| 1 Jul 2021 | $17.7M | $8.37M – $38.8M | $25.5M (+44%) | after a round | 3 | unknown | C | 0% |
| 1 Aug 2021 | $18.8M | $8.37M – $38.8M | $25.5M (+36%) | after a round | 3 | unknown | C | 0% |
| 1 Sep 2021 | $19.9M | $8.37M – $38.8M | $25.5M (+28%) | after a round | 3 | unknown | C | 0% |
| 1 Oct 2021 | $21.1M | $8.37M – $38.8M | $25.5M (+21%) | after a round | 3 | unknown | C | 0% |
| 1 Nov 2021 | $22.4M | $8.37M – $38.8M | $25.5M (+14%) | after a round | 3 | unknown | C | 0% |
| 1 Dec 2021 | $23.7M | $8.37M – $38.8M | $25.5M (+8%) | after a round | 3 | unknown | C | 0% |
| 1 Jan 2022 | $25.1M | $8.37M – $38.8M | $25.5M (+1%) | after a round | 3 | unknown | C | 0% |
| 1 Feb 2022 | $34.6M | $11.4M – $52.6M | $34.6M (0%) | after a round | 12 | growing | C | 0% |
| 1 Mar 2022 | $34.6M | $11.4M – $52.6M | $34.6M (0%) | after a round | 12 | growing | C | 0% |
| 1 Apr 2022 | $34.6M | $11.5M – $52.6M | $34.6M (0%) | after a round | 12 | growing | C | 0% |
| 1 May 2022 | $34.6M | $11.5M – $52.6M | $34.6M (0%) | after a round | 12 | growing | C | 0% |
| 1 Jun 2022 | $34.6M | $11.6M – $52.6M | $34.6M (0%) | after a round | 12 | growing | C | 0% |
| 10 Jun 2022 | $128M | $89.9M – $326M | $230M (+80%) | after a round | 12 | growing | C | 0% |
| 1 Jul 2022 | $132M | $89.9M – $326M | $230M (+74%) | after a round | 12 | growing | C | 0% |
| 1 Aug 2022 | $139M | $89.9M – $326M | $230M (+65%) | after a round | 12 | unknown | C | 0% |
| 1 Sep 2022 | $146M | $89.9M – $326M | $230M (+57%) | after a round | 12 | unknown | C | 0% |
| 1 Oct 2022 | $153M | $89.9M – $326M | $230M (+50%) | after a round | 12 | unknown | C | 0% |
| 1 Nov 2022 | $161M | $89.9M – $326M | $230M (+43%) | after a round | 12 | unknown | C | 0% |
| 1 Dec 2022 | $169M | $89.9M – $326M | $230M (+36%) | after a round | 12 | unknown | C | 0% |
| 1 Jan 2023 | $193M | $104M – $376M | $265M (+38%) | after a round | 23 | growing | C | 0% |
| 1 Feb 2023 | $205M | $104M – $376M | $265M (+29%) | after a round | 23 | growing | C | 0% |
| 1 Mar 2023 | $217M | $104M – $376M | $265M (+22%) | after a round | 23 | growing | C | 0% |
| 1 Apr 2023 | $231M | $104M – $376M | $265M (+15%) | after a round | 23 | growing | C | 0% |
| 1 May 2023 | $245M | $104M – $376M | $265M (+8%) | after a round | 23 | growing | C | 0% |
| 1 Jun 2023 | $261M | $104M – $376M | $265M (+2%) | after a round | 23 | growing | C | 0% |
| 1 Jul 2023 | $265M | $105M – $376M | $265M (0%) | after a round | 23 | growing | C | 0% |
| 1 Aug 2023 | $265M | $106M – $376M | $265M (0%) | after a round | 23 | growing | C | 0% |
| 1 Sep 2023 | $265M | $90.4M – $376M | $265M (0%) | after a round | 23 | unknown | C | 0% |
| 1 Oct 2023 | $265M | $86.1M – $376M | $265M (0%) | after a round | 23 | unknown | C | 0% |
| 1 Nov 2023 | $298M | $125M – $422M | $298M (0%) | after a round | 39 | growing | C | 0% |
| 1 Dec 2023 | $298M | $126M – $422M | $298M (0%) | after a round | 39 | growing | C | 0% |
| 1 Jan 2024 | $298M | $128M – $422M | $298M (0%) | after a round | 39 | growing | B | 0% |
| 1 Feb 2024 | $298M | $130M – $422M | $298M (0%) | after a round | 39 | growing | B | 0% |
| 1 Mar 2024 | $298M | $132M – $422M | $298M (0%) | after a round | 39 | growing | B | 0% |
| 1 Apr 2024 | $309M | $139M – $438M | $309M (0%) | after a round | 46 | growing | B | 0% |
| 1 May 2024 | $309M | $141M – $438M | $309M (0%) | after a round | 46 | growing | B | 0% |
| 1 Jun 2024 | $309M | $143M – $438M | $309M (0%) | after a round | 46 | growing | B | 0% |
| 1 Jul 2024 | $309M | $82.4M – $438M | $308M (0%) | after a round | 46 | up | C | 0% |
| 1 Aug 2024 | $309M | $79.9M – $438M | $307M (-1%) | after a round | 46 | up | C | 0% |
| 1 Sep 2024 | $310M | $77.8M – $440M | $307M (-1%) | after a round | 47 | up | C | 0% |
| 1 Oct 2024 | $310M | $75.6M – $440M | $306M (-1%) | after a round | 47 | up | C | 0% |
| 1 Nov 2024 | $310M | $73.3M – $440M | $305M (-2%) | after a round | 47 | up | C | 0% |
| 1 Dec 2024 | $299M | $48.2M – $425M | $287M (-4%) | after a round | 40 | flat | D | 0% |
| 1 Jan 2025 | $299M | $45.8M – $425M | $285M (-5%) | after a round | 40 | flat | D | 0% |
| 1 Feb 2025 | $299M | $43.5M – $425M | $283M (-5%) | after a round | 40 | flat | D | 0% |
| 1 Mar 2025 | $299M | $41.6M – $425M | $281M (-6%) | after a round | 40 | flat | D | 0% |
| 1 Apr 2025 | $299M | $39.5M – $425M | $279M (-7%) | after a round | 40 | flat | D | 0% |
| 1 May 2025 | $138M | $37.6M – $408M | $94.3M (-32%) | after a round | 40 | down | D | 63% |
| 1 Jun 2025 | $135M | $35.7M – $414M | $91.7M (-32%) | after a round | 40 | down | D | 63% |
| 1 Jul 2025 | $124M | $34.0M – $350M | $91.3M (-26%) | after a round | 40 | down | D | 63% |
| 1 Aug 2025 | $120M | $32.3M – $347M | $88.8M (-26%) | after a round | 40 | down | D | 63% |
| 1 Sep 2025 | $127M | $31.1M – $353M | $95.5M (-25%) | after a round | 42 | flat | D | 58% |
| 1 Oct 2025 | $133M | $29.6M – $355M | $101M (-24%) | after a round | 42 | down | D | 53% |
| 1 Nov 2025 | $139M | $28.2M – $359M | $107M (-23%) | after a round | 43 | flat | D | 49% |
| 1 Dec 2025 | $144M | $26.9M – $360M | $113M (-22%) | after a round | 43 | flat | D | 45% |
| 1 Jan 2026 | $150M | $25.6M – $361M | $118M (-21%) | after a round | 43 | flat | D | 42% |
| 1 Feb 2026 | $154M | $24.3M – $361M | $124M (-20%) | after a round | 43 | flat | D | 38% |
| 1 Mar 2026 | $161M | $23.2M – $366M | $133M (-18%) | after a round | 43 | flat | D | 35% |
| 1 Apr 2026 | $169M | $28.5M – $373M | $141M (-16%) | after a round | 45 | up | D | 32% |
| 1 May 2026 | $174M | $27.6M – $374M | $148M (-15%) | after a round | 45 | up | D | 30% |
| 1 Jun 2026 | $180M | $26.9M – $378M | $156M (-13%) | after a round | 47 | up | D | 27% |
| 1 Jul 2026 | $185M | $19.3M – $385M | $162M (-13%) | after a round | 46 | flat | D | 25% |
| 1 Aug 2026 | $189M | $18.3M – $385M | $168M (-11%) | after a round | 46 | flat | D | 23% |
| 1 Sep 2026 | $193M | $17.4M – $384M | $173M (-10%) | after a round | 46 | flat | D | 21% |
| 1 Oct 2026 | $195M | $16.5M – $380M | $176M (-10%) | after a round | 45 | flat | D | 20% |
| 24 Oct 2026 | $157M | $12.9M – $378M | $144M (-8%) | after a round | 45 | flat | D | 20% |
Key facts about Peptone
- Founded
- 2018
- Headquarters
- Bellinzona, Switzerland
- Employees
- about 45 +7% in a year
- Total raised
- $43M
- Funding rounds
- 2
- Last round
- Series A Jun 2022
Peptone was founded in 2018 by Kamil Tamiola.
Peptone funding history
Peptone has 2 funding rounds on record, from Jan 2021 to Jun 2022, $43M in total. None disclosed a valuation.
Series A 9 Jun 2022
Led by F-Prime Capital, Bessemer Venture Partners; with Walden Catalyst, Hoxton Ventures, dRX Capital.
Sources: techfundingnews.com, peptone.io, foundersfactory.com
$40M
$2.5M
Peptone investors
5 investors have backed Peptone; Hoxton Ventures, Bessemer Venture Partners and F-Prime Capital led at least one round.
- Hoxton Ventures lead, 2 rounds
- Bessemer Venture Partners lead
- F-Prime Capital lead
- dRX Capital 2 rounds
What Peptone does
Peptone works in biotechnology, with 14 recorded offerings and customers in biotechnology and pharmaceuticals.
Peptone Ltd. is a Swiss biotechnology company engaged in the design of small-molecule therapeutics targeting intrinsically disordered proteins (IDPs). The company utilizes artificial intelligence and experimental physics to develop small molecules for complex proteins, with a focus on therapeutic applications for diseases caused by protein misfolding. Peptone operates a Biosafety Level 2 laboratory in Bellinzona, Switzerland, conducting research activities such as target expression, characterization, assay development, and biological efficacy testing. The company collaborates with academic and industry partners to develop proprietary technologies, including hydrogen-deuterium exchange mass spectrometry, GPU-accelerated IDP modeling, and generative AI molecule design, supporting translational science by integrating experimental data with AI-driven predictions. Peptone serves the pharmaceutical and biotechnology industries.
Description from Veridion's company data.
Products and services
- Small-Molecule Therapeutics Design and Development
- Intrinsically Disordered Protein Target Identification
- AI-Driven Molecule Design and Optimization
- Experimental Physics-Based Drug Discovery
- Biosafety Level 2 Laboratory Research Services
- Target Expression and Characterization Services
- Assay Development and Biological Efficacy Testing
- Hydrogen-Deuterium Exchange Mass Spectrometry Services
- GPU-Accelerated IDP Modeling and Simulation
- Generative AI Molecule Design Services
- Proprietary Software Suite Development
- Experimental and AI Data Integration Services
- Translational Science Support Services
- Academic and Industry Technology Collaboration Services
Markets
- Biotechnology
- Pharmaceuticals
Technology
- Bespoke Hydrogen-Deuterium Exchange Mass Spectrometry
- GPU-Accelerated IDP Modeling
- Generative AI Molecule Design
Business model
- Business-to-Business
- Manufacturing
- Enterprise
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Peptone
What is Peptone worth?
Valuation $157M (range $12.9M to $378M), as of 24 Oct 2026.
Has Peptone raised money?
Peptone has 2 funding rounds on record, from Jan 2021 to Jun 2022, $43M in total. None disclosed a valuation.
Who has invested in Peptone?
Hoxton Ventures, Bessemer Venture Partners, F-Prime Capital, dRX Capital and Walden Catalyst. Lead investors include Hoxton Ventures, Bessemer Venture Partners and F-Prime Capital.
How many people work at Peptone?
About 45, up 7% over the last year. Headcount grew from 3 in Jan 2021 to 45 in Sep 2026.
What does Peptone do?
Peptone works in biotechnology, with 14 recorded offerings and customers in biotechnology and pharmaceuticals. Its main offerings are small-molecule therapeutics design and development, intrinsically disordered protein target identification and AI-Driven molecule design and optimization.
When was Peptone founded, and where is it based?
Peptone was founded in 2018 and is based in Bellinzona, Switzerland. It has about 45 employees, up 7% over the last year.